Mobic (meloxicam) Tablets
The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
For relief of the signs and symptoms of osteoarthritis
General Information
Mobic is a once-daily, 7.5 mg tablet indicated for the relief of
the pain and stiffness associated with osteoarthritis. Mobic is a
non-steroidal anti-inflammatory drug (NSAID).
Osteoarthritis is a disease which affects approximately 80% of
Americans over the age of 65. The disease, which causes the
cartilage in the joints to break down, is especially painful and
debilitating.
Clinical Results
A double-blind, controlled study was conducted in the U.S. to
evaluate the safety and efficacy of Mobic. The 12-week study
involved 464 patients who had osteoarthritis of the knee and hip.
When three different doses of Mobic (3.5 mg, 7.5 mg, and 15 mg
daily) were compared to placebo, results indicated that both the
7.5 and 15 mg daily doses of Mobic significantly decreased symptoms
of pain, function, and stiffness in patients, with a low incidence
of gastrointestinal side effects.
Six similar studies were conducted outside of the U.S. Results
were consistent with those found in the U.S. study.
Side Effects
Although Mobic tablets are generally well-tolerated
gastrointestinally, gastrointestinal ulcers may develop without
warning symptoms. While taking Mobic, specific attention should be
paid to any sign of gastrointestinal bleeding.
Do not use Mobic if:
- you have a known allergy to meloxicam, aspirin or other
NSAIDs
- you are, or may be, pregnant
Mechanism of Action
Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) that
exhibits anti-inflammatory, analgesic, and antipyretic activities
in models. The mechanism of action of meloxicam, like that of other
NSAIDs, may be related to prostaglandin synthetase (cyclooxygenase)
inhibition.
(From FDA Label)
Additional Information
Mobic, which will be marketed jointly in the U.S. by Boehringer
Ingelheim Pharmaceuticals, Inc. and Abbott Laboratories, will be
priced approximately 20% less than some other osteoarthritis drugs
in its class.
Visit the
Boehringer Ingelheim
Pharmaceuticals, Inc. web site to learn more about Mobic and
about other products, research, and services provided by the
company that developed this drug.
For more information about osteoarthritis and research and
treatments in this field, visit the web site of the Arthritis
Foundation:
www.arthritis.org
